Johnson & Johnson (JNJ) and its partner Bayer AG (BAYN) suffered a blow when FDA rejected for the second time the extended use of Xarelto, a blood thinner, to treat heart disease and reduce the risk of heart attacks.
Xarelto is an approved drug to prevent blood clots in patients undergoing hip and knee surgeries and to prevent stroke in patients with irregular heartbeats.
New Blood Thinner More Effective Than Warfarin
A new blood thinner developed by Bristol-Myers Squibb and Pfizer Inc was found to be more effective than warfarin in the Phase III trials conducted by the companies.
Advertisement
Earlier in July 2012, FDA had denied the approval to use Xarelto on heart patients stating missing data of around 1000 patients towards the end of the study.
On tracking down the data from patients who withdrew from the study, the overall results were positive. The drug when used with other regular drugs had the efficiency to reduce the risk of death due to heart disease by 16%.
However, the risk of bleeding increased by nearly four times, which outweighed the efficacy of Xarelto in preventing heart attacks. This has greatly influenced FDA's decision to reject the blood thinner to treat heart patients.
Source: Medindia
However, the risk of bleeding increased by nearly four times, which outweighed the efficacy of Xarelto in preventing heart attacks. This has greatly influenced FDA's decision to reject the blood thinner to treat heart patients.
Source: Medindia
Big No to Combining Blood Thinners With Acid Reflux Tablets After a Heart Attack
Combo of heartburn drugs and Blood thinners after a heart attack could be lethal as per a recent study.
Advertisement
 Indications of Anticoagulant Therapy or Blood ThinnersAnticoagulants are used to prevent and treat deep vein thrombosis, pulmonary and cerebral embolism, unstable angina, heart attack, atrial fibrillation and disseminated intravascular coagulation. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.